New York, NY – November 6, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will be featured at the SeeThruEquity Fall Microcap Investor Conference in New York City. Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, is scheduled to deliver the presentation at the Convene Midtown East on November 12, 2014 at 11:30 AM EST.
With Anavex’s recent Phase 2a clinical trial approval, the conference is an opportune time for Dr. Missling to provide investors and the financial community with a business overview. The Phase 2a Alzheimer’s disease trial is currently underway with the Company’s proprietary compound, ANAVEX 2-73, and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®). Management plans to be available for one-on-one meetings with members of the investment community at the conference. Attendees are also invited to contact Anavex in advance at firstname.lastname@example.org to request a meeting with Dr. Missling.
ANAVEX 2-73 is a proprietary small molecule that targets sigma-1 and muscarinic receptors. Preclinical results indicate that the anti-Alzheimer’s compound has the potential to halt and/or reverse the course of the disease. ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), shows a highly encouraging synergistic effect in Alzheimer’s disease models, producing up to 80% greater reversal of memory loss and neuroprotection when used in combination, versus when the drugs were administered individually.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other Central Nervous System (CNS) diseases, and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development